Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6616591 | 0.74 | CYP1A2 (0.48) | P2RX7POLBRAB9AADORA3ADORA2A | |
| SCHEMBL7864142 | 0.73 | NOTUM (0.56) | NOTUMHTTALDH1A1 | |
| SCHEMBL17080299 | 0.68 | NOTUM (0.39) | NOTUMGAACYP3A4P2RX7HPGD | |
| SCHEMBL7220247 | 0.65 | HTR3E (0.41) | GAACYP3A4HPGDL3MBTL1SMN1; SMN2 | |
| SCHEMBL8443367 | 0.64 | CYP11B1 (0.40) | CYP3A4L3MBTL1SMN1; SMN2MAOAALOX15 | |
| SCHEMBL69609 | 0.64 | NOTUM (0.39) | NOTUMGAACYP3A4P2RX7HPGD | |
| SCHEMBL4717229 | 0.61 | GAA (0.47) | NOTUMGAAP2RX7HPGDL3MBTL1 | |
| SCHEMBL274416 | 0.61 | NOTUM (0.39) | NOTUMGAAP2RX7L3MBTL1SMN1; SMN2 | |
| SCHEMBL430176 | 0.60 | GAA (0.42) | NOTUMGAAP2RX7HPGDL3MBTL1 | |
| SCHEMBL342739 | 0.60 | NOTUM (1.00) | NOTUMSMN1; SMN2KDM4ERAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | claimed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | claimed |
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | claimed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | claimed |
| EP-1836211-A1 | MACROLIDES | Pfizer Products Incorporated (US) | 2007-09-26 | — | — | EP | claimed |
| WO-2006067589-A1 | MACROLIDES | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | claimed |
| EP-4330236-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-4183752-A | DEVELOPMENT INHIBITOR RELEASING THIOETHERS | AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) | 1980-01-15 | — | — | US | disclosed |
| US-4174969-A | THIOETHER DEVELOPMENT INHIBITOR COMPOUND | AGFA-GEVAERT, A.G. (DE) | 1979-11-20 | — | — | US | disclosed |
| US-4171223-A | DEVELOPMENT INHIBITOR COMPRISING A 1,2,5-THIADIAZOLINE-1,1-DIOXIDE COMPOUND | AGFA-GEVAERT, A.G. (DE) | 1979-10-16 | — | — | US | disclosed |
| US-4088491-A | COLOR PHOTOGRAPHY, THIOETHERS, NONDIFFUSING | AGFA-GEVAERT AKTIENGESELLSCHAFT (DT) | 1978-05-09 | — | — | US | disclosed |
| US-4052213-A | OXAZOLINONE-2-COMPOUNDS CONTAINING A MERCAPTO GROUP | AGFA-GEVAERT, A.G. (DT) | 1977-10-04 | — | — | US | disclosed |
| US-4046574-A | COLOR PHOTOGRAPHIC MATERIAL WITH HOMOPHTHALIMIDE THIOETHER DEVELOPMENT INHIBITOR | AGFA-GEVAERT, AKTIENGESELLSCHAFT (DT) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | NOTUM 4602/4885GAA 4545/4885CYP3A4 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.